Related Experiment Videos
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
James B Brugarolas1, Francisca Vazquez, Archana Reddy
1Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
Cancer Cell
|September 6, 2003
Summary
Loss of the TSC2 tumor suppressor protein increases vascular tumors by regulating VEGF. This occurs through both mTOR-dependent and -independent pathways, potentially involving chromatin remodeling.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Tuberous sclerosis complex (TSC) is caused by TSC2 inactivation, leading to vascular tumors.
- TSC2 protein inhibits mTOR (mammalian target of Rapamycin), a key cellular regulator.
- VEGF (Vascular Endothelial Growth Factor) is crucial for tumor vascularization.
Purpose of the Study:
- To investigate the regulatory mechanisms of VEGF by TSC2.
- To elucidate the roles of mTOR-dependent and -independent pathways in TSC2-mediated VEGF regulation.
- To explore potential therapeutic targets for TSC-associated tumors.
Main Methods:
- Cellular assays using TSC2-deficient cells and disease-associated mutants.
- Western blotting to assess protein levels (HIF-1alpha, VEGF).
- Treatment with Rapamycin (mTOR inhibitor) and Trichostatin A (HDAC inhibitor).
Main Results:
- TSC2 loss leads to HIF-1alpha accumulation and increased VEGF expression.
- Rapamycin normalizes HIF-1alpha levels in TSC2-deficient cells, confirming mTOR-dependent regulation.
- Rapamycin only partially reduces VEGF, indicating an mTOR-independent pathway.
- Trichostatin A downregulates VEGF in TSC2-deficient cells, suggesting chromatin remodeling involvement.
Conclusions:
- TSC2 regulates VEGF through both mTOR-dependent and -independent pathways.
- The mTOR-independent pathway may involve epigenetic modifications like chromatin remodeling.
- Understanding these pathways offers insights into TSC pathogenesis and potential therapeutic strategies.